efavirenz, lamivudine and tenofovir disoproxil fumarate
- Product NDC
- 33342-362
- 11-digit product format
- 333420362
- Labeler code
- 33342
- Product ID
- 33342-362_648bf898-b7be-497c-b935-cfa5c057b318
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- efavirenz, lamivudine and tenofovir disoproxil fumarate
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Macleods Pharmaceuticals Limited
- Application
- NDA210649
- Marketing category
- NDA
- Marketing start
- 2019-03-29
- Marketing end
- 0000-00-00
- Substance
- EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- Active strength
- 400 mg/1; mg/1; mg/1
- Pharmacologic classes
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [EXT],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record